reports
Resolutions from the Annual General Meeting 2025
Resolutions from the Annual General Meeting 2025 Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2024Approval of distribution of profit with payment of an ordinary dividend of DKK 4.20 (corresponding to approximately EUR 0.56) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.00 (EUR ~0.27) was disbursed on September 3, 2024.Approval of the Remuneration Report for 2024 (advisory vote)Approval of the remuneration of members of the Board of Direc...
Invitation to the Annual General Meeting
Invitation to the Annual General Meeting The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Thursday April 3, 2025 at 4:00 pm CEST at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please read the attached PDF documents. Attachments
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment
Election of employee representatives to the Board of Directors
Election of employee representatives to the Board of Directors The employees have conducted the election of employee representatives to the Board of Directors of Novonesis (Novozymes A/S). The following employee representatives (in alphabetical order after surname) were elected for the next four years: Robert Nøddeskov Jensen, Senior Operator - newly electedLars Bo Køppler, Technician - newly electedPreben Nielsen, Science Manager – re-electedFrederikke Rose Spenner, Production Engineer - newly elected As alternates to the employee representatives to the Board of Directors, the employe...
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please see attached the full announcement. Attachment
Initiation of share buyback program
Initiation of share buyback program On March 5, 2025, Novonesis will initiate a share buyback program as announced in Company Announcement No. 3 of February 26, 2025. Under the program, Novonesis will buy back B shares worth up to EUR 100 million in total during the remainder of 2025, corresponding to around 1.7 million B shares at the current share price. The program is contingent upon no major strategic initiatives being decided upon that will require a significant amount of capital. The shares acquired in the program will be used to meet obligations arising from employee share-based inc...
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please see attached the full announcement. Attachment
Trading by management and close relations of management
Trading by management and close relations of management The Executive Leadership Team members eligible for the Novozymes A/S 2022-2024 incentive program has on February 26, 2025, received the allocated shares. An overview of the number and value of shares allotted is provided on the attached file. Attachment
12M 2024: Novonesis delivers strong full-year results and expects cont...
12M 2024: Novonesis delivers strong full-year results and expects continued growth in 2025 Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of 37-38%. COPENHAGEN, Denmark – February 26, 2025. In the 2024 financial year, Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin at 36.1%. The sales growth is driven by both Food & Health Biosolutions and Planetary Health Biosolutions. Volumes have increased by ~6% with pricing contribu...
12M 2024 Company announcement
12M 2024 Company announcement 2024 organic pro forma sales growth of 8%, with pro forma adjusted EBITDA margin of 36.1%. 2025 outlook of 5-8% organic pro forma sales growth and 37-38% adjusted EBITDA margin. 2024 organic pro forma sales growth of 8% (Q4: 7%) and 8% on IFRS reported basis (Q4 7%). Food & Health Biosolutions at 7%, and Planetary Health Biosolutions at 9%.2024 pro forma adjusted EBITDA margin of 36.1% (2H 36.8%), with 35.2% for Food & Health Biosolutions and 36.8% for Planetary Health Biosolutions. 2024 adjusted EBITDA margin on IFRS reported base of 36.2% (2H 36.8%).2024 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.